In the study of Lim et al., in which 8/18 patients in the ON trial and 15/32 subjects in the MS attack trial were treated with oral methylprednisolone, in the MS attack trial group, CSF NF-HSM134 and NF-HSM135 measured at week 3 and CSF NF-HSM134levels from baseline to week 3 were predictive of clinical outcome at week 8 and 52 [78]. This evidence concerns the gene NFASC and myeloid sarcoma.